Specific and efficient anti-Aβ42 antibodies induced by sixteen tandem repeats of Aβ9.

To reduce the risk of an adverse T cell-mediated immune response to Aβ42, three (Aβ9)16-based recombinant immunogens were designed to immunize mice. Compared with Aβ42, they elicited significantly stronger anti-Aβ42 antibody responses and mainly resulted in IgG1 and IgG2b anti-Aβ42 antibodies. These (Aβ9)16-induced antibodies exhibited stronger abilities not only to inhibit Aβ42 aggregation and to disassemble Aβ42 aggregation, but also to inhibit and neutralize Aβ42-induced cytotoxicity in vitro though they showed higher specificities to Aβ42 monomers and Aβ42 oligomers. These results suggested that (Aβ9)16 was a promising candidate for the safe and effective primary immunogen against Aβ42.